Indalo Therapeutics Names Robert Jacks President & CEO

11:50 EST 28 Jan 2019 | Xconomy

Indalo Therapeutics has appointed Robert Jacks to serve as president and CEO. Jacks was most recently president and chief financial officer of Symbiomix Therapeutics, which was acquired by Lupin in 2017. Indalo was formed by the 2016 merger of Antegrin Therapeutics and Cascadia Therapeutics. The Cambridge, MA-based company’s lead drug candidate, IDL-2965, is expected to […]

Original Article: Indalo Therapeutics Names Robert Jacks President & CEO


More From BioPortfolio on "Indalo Therapeutics Names Robert Jacks President & CEO"

Quick Search


Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...